

Notice: This is a translation of a notice in Japanese and is made solely for the convenience of foreign shareholders. In the case of any discrepancy between the translation and the Japanese original, the latter shall prevail.

[Translation]

November 28, 2022

To: Shareholders

Company Name: Renascience Inc.

Name of Representative: Koji Naito, President & CEO

(Code: 4889 TSE Growth)

Inquiries: Hiroyasu Ishimaru, Corporate Officer in charge of Administration and Corporate Planning

Notice of Conclusion of Memorandum of Understanding with Daiichi Sankyo Company, Limited to Amend Agreement Concerning Preferential Negotiation Rights with Option Rights

The Company hereby announces that the Company has agreed to execute a Memorandum of Understanding to the Agreement concerning Preferential Negotiation Rights with Option Right dated on December 25, 2020 with Daiichi Sankyo Company, Limited ("Daiichi Sankyo") that has been amended on October 26, 2021 and on June 9, 2022 (hereinafter the Agreement and the amendments are referred to as the Original Agreement" collectively), to further extend the "Option Period" of which has been extended to December 31, 2022 by the above amendments, to March 31, 2025.

Under the terms of the Original Agreement, the Company grants Daiichi Sankyo the option and priority negotiation rights to develop and commercialize RS5614, a plasminogen activator inhibitor-1 inhibitor (the "Drug Candidate"), for the treatment of lung diseases including novel coronavirus pneumonia and other lung injuries.

The Memorandum of Understanding stipulates that the Option Period is further extended with a view to conducting clinical trials to confirm the efficacy of the Drug Candidate in interstitial pneumonia arising from the treatment with the anticancer drug, and other indications. Under the Memorandum of Understanding, the Company will receive 10 million yen from Daiichi Sankyo as consideration for the extension of the option period.

The impact on the full-year results for the fiscal year ending March 31, 2023 is expected to be immaterial, but we will promptly announce any matters that should be disclosed in the future.

End